RNA, U2 small nuclear 17, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU2-17P profile across patient tissues and cancer cell-line models. RNU2-17P expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RNU2-17P is differentially expressed in 6, with the highest sampling consensus in KICH. Additionally, RNU2-17P RNA expression shows 13,174 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KICH as cancer lineages where RNU2-17P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU2-17P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU2-17P survival associations across molecular data types. RNU2-17P RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU2-17P RNA expression–survival associations across cancer types. High RNU2-17P expression shows unfavorable associations in ACC, LUSC, LUAD, KIRP and THYM, but favorable associations in CHOL. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RNU2-17P RNA expression.
This table summarizes RNU2-17P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for RNU2-17P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU2-17P shows lower tumor expression in KICH, BRCA, PRAD and HNSC and higher tumor expression in LIHC and CHOL. The KICH box plot shows higher RNU2-17P RNA expression in normal versus tumor tissue (log2 FC = −0.956, t-test p < 0.001).
This table shows molecular features associated with RNU2-17P in patient tissues and cancer cell lines. In patient samples, RNU2-17P shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
